Meeting
2023 ASCO Annual Meeting
A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.
Authors
Satoshi Watanabe
Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Satoshi Watanabe , Naoki Furuya , Atsushi Nakamura , Jun Shiihara , Ichiro Nakachi , Hisashi Tanaka , Mika Nakao , Koichi Minato , Masahiro Seike , Shinichi Sasaki , Akira Kisohara , Susumu Takeuchi , Ryoichi Honda , Kei Takamura , Yiwei Ling , Shujiro Okuda , Hiroshi Kagamu , Kenichi Yoshimura , Toshiaki Kikuchi , Kunihiko Kobayashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
jRCTs031190066
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9079)
DOI
10.1200/JCO.2023.41.16_suppl.9079
Abstract #
9079
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
First Author: Naoki Furuya
Poster
2021 ASCO Annual Meeting
Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency.
First Author: Leeseul Kim
Poster
2020 ASCO Virtual Scientific Program
A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
First Author: Sehhoon Park
Poster
2023 ASCO Annual Meeting
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
First Author: Xiuning Le